Rheumatology Providers, FDA Leaders Discuss Biosimilar Policy Challenges and Opportunities at National Policy Briefing
June 20, 2016 18:41 ET
|
American College of Rheumatology
WASHINGTON, June 20, 2016 (GLOBE NEWSWIRE) -- Experts from the American College of Rheumatology (ACR), Food and Drug Administration (FDA), and other leading national healthcare groups spoke about the...
Two-Thirds of Biopharma Sponsors Surveyed Currently Sell or Plan to Sell Biosimilar Products
May 17, 2016 11:00 ET
|
Industry Standard Research
CARY, NC--(Marketwired - May 17, 2016) - A new report titled Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (3rd edition) from Industry Standard Research (ISR),...
EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes
May 09, 2016 16:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
New strategy to focus exclusively on BOW080 (eculizumab biosimilar) and BOW070 (tocilizumab biosimilar) in rare diseases with a combined target market opportunity of close to $6 billion of innovator...
EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update
March 15, 2016 06:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, March 15, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the global development and commercialization of biosimilar...
EPIRUS Biopharmaceuticals to Release Fourth Quarter and Fiscal Year 2015 Financial Results and Provide Business Update
March 01, 2016 08:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, March 01, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a pure-play biosimilar company focused on the development and commercialization of biosimilar monoclonal...
American College of Rheumatology Encourages Safe Adoption of Biosimilars During FDA Public Hearing on CT-P13, a Proposed Biosimilar for Infliximab (Remicade)
February 10, 2016 14:43 ET
|
American College of Rheumatology
ATLANTA, Feb. 10, 2016 (GLOBE NEWSWIRE) -- During a public meeting held Tuesday by the Food and Drug Administration (FDA)'s Arthritis Advisory Committee to review the license application of CT-P13,...
EPIRUS Biopharmaceuticals Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)
February 09, 2016 07:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
UNIFORMi Study builds on prior successful Phase 1 and Phase 3 studiesIntended to support harmonized global filing for BOW015 in 2017BOW015 is a biosimilar for Remicade®, which had global sales of...
EPIRUS Biopharmaceuticals to Participate in Bloomberg Intelligence Healthcare Event on February 12
February 05, 2016 16:01 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Feb. 05, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
EPIRUS Biopharmaceuticals to Present at LEERINK Partners 5th Annual Global Healthcare Conference
February 03, 2016 09:00 ET
|
EPIRUS Biopharmaceuticals, Inc.
BOSTON, Feb. 03, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and commercialization of biosimilar monoclonal...
FFF Enterprises Celebrates 10,000 Counterfeit-free Days
November 23, 2015 17:07 ET
|
FFF Enterprises
TEMECULA, Calif., Nov. 23, 2015 (GLOBE NEWSWIRE) -- On November 23, 2015, FFF Enterprises, Inc. celebrates reaching a historic feat of 10,000 counterfeit-free days. As the largest and most trusted...